Insmed, Inc. $INSM Shares Sold by TD Asset Management Inc

TD Asset Management Inc lowered its position in Insmed, Inc. (NASDAQ:INSM) by 21.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 395,194 shares of the biopharmaceutical company’s stock after selling 107,038 shares during the period. TD Asset Management Inc owned about 0.21% of Insmed worth $39,772,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in INSM. Cullen Frost Bankers Inc. lifted its position in Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 221 shares during the period. ORG Partners LLC lifted its position in Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 196 shares during the period. Hilltop National Bank acquired a new stake in Insmed in the second quarter valued at about $28,000. LRI Investments LLC acquired a new stake in Insmed in the second quarter valued at about $59,000. Finally, Signaturefd LLC lifted its position in Insmed by 60.0% in the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 325 shares during the period.

Insider Buying and Selling at Insmed

In other news, Director Melvin Md Sharoky sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the completion of the transaction, the director directly owned 262,675 shares of the company’s stock, valued at $38,190,318.25. This trade represents a 3.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Sara Bonstein sold 58,400 shares of the firm’s stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the transaction, the chief financial officer directly owned 73,505 shares of the company’s stock, valued at approximately $7,546,758.35. This trade represents a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 211,057 shares of company stock worth $27,438,126. 3.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on INSM shares. Morgan Stanley raised their price objective on shares of Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a research report on Thursday, August 21st. Evercore ISI reiterated an “outperform” rating and set a $180.00 price target on shares of Insmed in a research report on Wednesday, October 1st. William Blair assumed coverage on shares of Insmed in a research report on Wednesday, August 20th. They set an “outperform” rating for the company. Cowen reiterated a “buy” rating on shares of Insmed in a research report on Thursday, October 2nd. Finally, Royal Bank Of Canada lifted their price target on shares of Insmed from $108.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $152.88.

Insmed Trading Down 0.2%

Shares of INSM opened at $163.19 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The firm has a 50 day simple moving average of $142.26 and a 200-day simple moving average of $104.19. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $166.44. The stock has a market cap of $34.50 billion, a price-to-earnings ratio of -28.58 and a beta of 1.03.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million for the quarter, compared to analysts’ expectations of $104.06 million. During the same period last year, the business earned ($1.94) earnings per share. The company’s revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. Equities analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.